Last reviewed · How we verify

Congenital neutropenia — Treatment Landscape & Competitive Intelligence

Congenital neutropenia (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Congenital neutropenia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Neupogen Filgrastim-Aafi Amgen Colony-stimulating factor (CSF); leukocyte growth factor G-CSF receptor (granulocyte colony-stimulating factor receptor) 1991-01-01
Neupogen Neupogen University of Chicago Granulocyte colony-stimulating factor receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Amgen · 1 drug in Congenital neutropenia
  2. University of Chicago · 1 drug in Congenital neutropenia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Congenital neutropenia:

Cite this brief

Drug Landscape (2026). Congenital neutropenia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/congenital-neutropenia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing